methyl 6-[N-(2-hydroxy-3-methoxybenzoyl)amino] hexanoate | 156806-81-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 6-[N-(2-hydroxy-3-methoxybenzoyl)amino] hexanoate
• 英文别名: methyl 6-[N-(2-hydroxy-3-methoxybenzoyl)amino]hexanoate；methyl 6-[(2-hydroxy-3-methoxybenzoyl)amino]hexanoate
• CAS: 156806-81-4
• 化学式: C₁₅H₂₁NO₅
• 分子量: 295.335
• InChiKey: HDJFTLBAHAYRIL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  21
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-(chlorocarbonyl)-6-methoxyphenyl acetate 、 6-氨基己酸甲酯 盐酸盐 以 水 、 乙酸乙酯 、 三乙胺 、 Petroleum ether 、 苯 为溶剂， 以1.62 g (55%)的产率得到methyl 6-[N-(2-hydroxy-3-methoxybenzoyl)amino] hexanoate
  参考文献：
  名称：

  N-benzoylamino acid derivatives, pharmaceutical compositions containing them and process for preparing same

  摘要：

  公开号：

  EP0576941B1

文献信息

• N-benzoyl amino acid derivatives pharmaceutical compositions containing
  申请人：Gyogyszerkutato Intezet KFT

  公开号：US05705529A1

  公开（公告）日：1998-01-06

  The invention relates to novel N-benzoylamino acid derivatives of the general formula (I), ##STR1## wherein R.sup.1 and R.sup.2, which are the same or different, stand for a hydroxyl group optionally bearing an acetyl group; or a C.sub.1-6 alkoxy group optionally substituted by a phenyl group; n means an integer from 2 to 15 as well as their tautomers, racemates and optically active individual (pure) isomers or mixtures thereof and the salts of these compounds and pharmaceutical compositions containing these compounds. The invention relates also to a process for the preparation of compounds of the general formula (I). The compounds of general formula (I) inhibit the peroxidation of lipids and therefore, they are expected to be useful for the treatment of diseases being in an indirect or direct connection with pathological oxidation processes, chiefly for the treatment and/or prevention of ischaemic and reperfusion tissue injuries, inflammatory reactions, atherosclerosis, various degenerative neurological disorders as well as for delaying the natural process of the ageing of cells.

  本发明涉及一种新颖的N-苯甲酰氨基酸衍生物，其一般式为（I）：##STR1## 其中R1和R2相同或不同，代表一个氢氧基，可选地带有乙酰基；或一个C.sub.1-6烷氧基，可选地被苯基取代；n代表2至15的整数，以及它们的互变异构体、外消旋体和光学活性单体（纯异构体）或其混合物以及这些化合物的盐和含有这些化合物的药物组成物。本发明还涉及一种制备一般式（I）化合物的方法。一般式（I）化合物抑制脂质的过氧化作用，因此，它们预计可用于治疗与病理氧化过程有间接或直接联系的疾病，主要用于治疗和/或预防缺血和再灌注组织损伤、炎症反应、动脉粥样硬化、各种退行性神经疾病以及延缓细胞自然衰老过程。
• N-benzoylamino acid derivatives, pharmaceutical compositions containing
  申请人：Gyogyszerkutato Intezet KFT

  公开号：US05854250A1

  公开（公告）日：1998-12-29

  An N-benzoylamino acid compound of the formula (I), ##STR1## wherein R.sup.3 is an NR.sup.4 R.sup.5 group where R.sup.4 and R.sup.5 which are the same or different are selected from the group consisting of hydrogen, a hydroxyl group, a C.sub.1-12 alkyl group, a C.sub.1-4 alkyl group substituted by a hydroxyl group and a C.sub.1-4 alkyl group substituted by an amino group; R.sup.4 and R.sup.5 when taken together with the adjacent nitrogen form a substituted or unsubstituted 5- or 6-membered heterocyclic group, a 5- or 6-membered heterocyclic group containing an additional nitrogen atom, a 5- or 6-membered heterocyclic group containing an additional nitrogen atom and being substituted by an oxo group, a phenyl-substituted C.sub.1-4 alkyl group or C.sub.3-5 alkenyl group; with the proviso that when the heterocyclic group is piperazine, this heterocyclic group may also be substituted by a diaminopyrimidinyl or di(pyrrolidino)-pyrimidinyl group; n is an integer from 2 to 15; and their tautomers, racemates and the pure optically active individual isomers or mixtures thereof, and a pharmaceutically acceptable salt thereof is described. These compounds are useful for the treatment of patients suffering from disorders being in an indirect or direct connection with pathological oxidation processes occurring in the organism, particularly ischaemic and reperfusion tissue injuries, inflammations, atherosclerosis, or degenerative neurological disorders.

  化合物(I)的N-苯甲酰氨基酸，其公式为：##STR1##其中，R.sup.3是NR.sup.4R.sup.5基团，其中R.sup.4和R.sup.5相同或不同，选择自氢、羟基、C.sub.1-12烷基、被羟基取代的C.sub.1-4烷基或被氨基取代的C.sub.1-4烷基的群；当R.sup.4和R.sup.5与相邻的氮一起形成取代或未取代的5-或6-成员杂环基团、含有额外氮原子的5-或6-成员杂环基团、含有额外氮原子且被氧代基取代的5-或6-成员杂环基团、苯基取代的C.sub.1-4烷基或C.sub.3-5烯基基团时，当杂环基团为哌嗪时，此杂环基团也可以被二氨基嘧啶基团或二(吡咯烷基)-嘧啶基团取代；n为2到15的整数；它们的互变异构体、外消旋体和纯光学活性的单一异构体或其混合物以及其药学上可接受的盐也被描述。这些化合物对于治疗患有与机体中发生的病理氧化过程间接或直接相关的疾病的患者特别有用，包括缺血和再灌注组织损伤、炎症、动脉硬化或变性神经疾病。
• US5705529A
  申请人：——

  公开号：US5705529A

  公开（公告）日：1998-01-06
• US5854250A
  申请人：——

  公开号：US5854250A

  公开（公告）日：1998-12-29
• N-benzoylamino acid derivatives, pharmaceutical compositions containing them and process for preparing same
  申请人：NISSHIN FLOUR MILLING CO., LTD.

  公开号：EP0576941B1

  公开（公告）日：1997-09-03